| P2093 | author name string | Amir Akhavan Rezayat | |
| | Fatemeh Behdani | |
| | Majid Nabizadeh Marvast | |
| | Mohamad Salaran | |
| | Paria Hebrani | |
| P2860 | cites work | Risperidone alone or in combination for acute mania | Q24244719 |
| | A rating scale for mania: reliability, validity and sensitivity | Q29619299 |
| | A systematic review of the global distribution and availability of prevalence data for bipolar disorder | Q33763161 |
| | The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 |
| | Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride | Q33959951 |
| | A review of randomized, controlled clinical trials in acute mania | Q34106683 |
| | Current pharmacotherapeutic approaches for the treatment of Tourette syndrome | Q34409626 |
| | The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania | Q34531273 |
| | Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability | Q34548876 |
| | Aripiprazole (Otsuka Pharmaceutical Co). | Q34675478 |
| | Mechanism of new antipsychotic medications: occupancy is not just antagonism | Q35558773 |
| | Role of aripiprazole in treating mood disorders | Q36688973 |
| | Aripiprazole acts as a selective dopamine D2 receptor partial agonist | Q36821350 |
| | Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability | Q37155306 |
| | Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. | Q37178608 |
| | Optimizing treatment outcomes in bipolar disorder under ordinary conditions | Q37183396 |
| | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review | Q37299210 |
| | Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis | Q37665567 |
| | Predicting the course and outcome of bipolar disorder: a review | Q37742880 |
| | Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials | Q38179151 |
| | Psychopharmacological interventions in autism spectrum disorder | Q38194907 |
| | The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release | Q40578840 |
| | Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study | Q43258937 |
| | Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 |
| | Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype | Q44080048 |
| | Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats | Q44675329 |
| | Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011. | Q44978259 |
| | Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol | Q45168624 |
| | Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study | Q46178044 |
| | Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | Q46681460 |
| | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 |
| | Bipolar disorder | Q77549686 |
| P433 | issue | 8 | |
| P921 | main subject | risperidone | Q412443 |
| P304 | page(s) | 733-738 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | Journal of Research in Medical Sciences | Q15816632 |
| P1476 | title | Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania | |
| P478 | volume | 19 | |